Samsara Biocapital, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Samsara Biocapital, LLC reported 40 stock positions worth $520.3 million. Its top holding was Cargo Therapeutics (CRGX) at 15.7% of the portfolio, followed by Mineralys Therapeutics (MLYS, 11.8%) and Scholar Rock (SRRK, 10.5%). Compared with Q2 2024, it opened 3 new positions, sold out of 1, added to 1 and reduced 6. The biggest buy was a new position in Alumis (ALMS) and the biggest sale Climb Bio (CLYM, shares −20%).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001744967
- Portfolio Value
- $520.3M (Q3 2024)
- SEC Filing
- 0001104659-24-118933 ↗ filed Nov 14, 2024
Holdings Value
Holdings 40 stocks · $520.3M
| CRGX Cargo Therapeutics Inc. | 15.66% | 4,415,689 | $81.5M | No change |
| MLYS Mineralys Therapeutics Inc. | 11.81% | 5,074,916 | $61.5M | No change |
| SRRK Scholar Rock Holding Corp. | 10.45% | 6,788,609 | $54.4M | No change |
| NGNE Neurogene Inc. | 10.22% | 1,267,790 | $53.2M | No change |
| ALMS Alumis Inc. | 6.71% | 3,266,498 | $34.9M | New |
| ACLX Arcellx Inc. | 5.68% | 353,641 | $29.5M | Reduce -22.0% |
| LENZ Lenz Therapeutics Inc. | 5.51% | 1,208,473 | $28.7M | No change |
| NKTX Nkarta Inc. | 3.27% | 3,768,035 | $17.0M | No change |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 2.55% | 2,609,114 | $13.3M | Reduce -20.0% |
| AVDL Avadel Pharmaceuticals Ltd. | 2.44% | 967,527 | $12.7M | No change |
| ZYME Zymeworks Inc. | 2.41% | 1,000,000 | $12.6M | No change |
| SLRN Acelyrin Inc. | 2.39% | 2,523,022 | $12.4M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 2.17% | 588,816 | $11.3M | Reduce 0.0% |
| JSPR Jasper Therapeutics Inc. | 2.11% | 584,642 | $11.0M | Add +11.4% |
| ABVX Abivax SA-ADR | 1.88% | 850,000 | $9.8M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 1.74% | 172,647 | $9.0M | No change |
| INZY Inozyme Pharma Inc. | 1.57% | 1,562,500 | $8.2M | No change |
| STRO Sutro Biopharma Inc. Com SHS | 1.46% | 2,196,814 | $7.6M | No change |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 1.21% | 2,442,352 | $6.3M | No change |
| GOSS Gossamer Bio Inc. | 1.16% | 6,130,268 | $6.0M | No change |
| VRNA Verona Pharma Ltd. | 1.08% | 195,225 | $5.6M | Reduce -43.8% |
| TNGX Tango Therapeutics Inc. | 0.93% | 630,000 | $4.9M | No change |
| ARTV Artiva Biotherapeutics Inc. | 0.87% | 291,666 | $4.5M | New |
| SYRS Syros Pharmaceuticals Inc. | 0.74% | 1,786,427 | $3.8M | No change |
| IOBTQ Io Biotech Inc. | 0.73% | 3,640,015 | $3.8M | No change |
| VTVT VTV Therapeutics Inc. Class A | 0.54% | 206,784 | $2.8M | No change |
| IMTX Immatics NV | 0.43% | 198,000 | $2.3M | No change |
| PRME Prime Medicine Inc. | 0.40% | 540,304 | $2.1M | No change |
| DAWN Day One Biopharmaceuticals I | 0.39% | 147,319 | $2.1M | Reduce -25.0% |
| TERN Terns Pharmaceuticals Inc. | 0.32% | 202,348 | $1.7M | No change |
| HLVX Hillevax Inc. | 0.27% | 799,274 | $1.4M | No change |
| JANX Janux Therapeutics Inc. | 0.20% | 22,526 | $1.0M | Reduce -50.0% |
| BCAX Bicara Therapeutics Inc. | 0.17% | 35,000 | $891K | New |
| ACRS Aclaris Therapeutics Inc. | 0.15% | 696,171 | $801K | No change |
| LYRA Lyra Therapeutics Inc. | 0.14% | 2,780,261 | $715K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.13% | 1,049,153 | $680K | No change |
| VIRX Viracta Therapeutics Inc. | 0.03% | 689,709 | $160K | No change |
| ALLK Allakos LLC | 0.02% | 172,089 | $112K | No change |
| KRON Kronos Bio Inc. | 0.01% | 78,131 | $78K | No change |
| ALLOVIR INC | 0.01% | 82,336 | $67K | No change |
Other holdings (2): bonds, preferreds, convertibles and warrants · $14K (not counted above)
Total filed on the 13F, all lines: $520.3M.
Portfolio Sells Q2 2024 → Q3 2024
| CLYM Climb Bio Inc. | Reduce -20.0% | 2.55% | −2.30 |
| IGMS Igm Biosciences Inc. | Sold out | 0.00% | −0.22 |
| JANX Janux Therapeutics Inc. | Reduce -50.0% | 0.20% | −0.20 |
| DAWN Day One Biopharmaceuticals I | Reduce -25.0% | 0.39% | −0.17 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce 0.0% | 2.17% | −0.00 |
| VRNA Verona Pharma Ltd. | Reduce -43.8% | 1.08% | +0.03 |
| ACLX Arcellx Inc. | Reduce -22.0% | 5.68% | +0.44 |
Portfolio Buys Q2 2024 → Q3 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 24 | $1.2B | SRRK, ALMS, MLYS, SEPN, ALMR |
| Q1 2026 | 22 | $1.0B | SRRK, MLYS, ALMS, SEPN, KLRS |
| Q4 2025 | 20 | $969.2M | SRRK, MLYS, KLRS, SEPN, ALMS |
| Q3 2025 | 25 | $765.9M | MLYS, SRRK, KLRS, SEPN, NGNE |
| Q2 2025 | 27 | $488.9M | SRRK, MLYS, SEPN, KLRS, NGNE |
| Q1 2025 | 35 | $560.8M | SRRK, KLRS, MLYS, NGNE, ALMS |
| Q4 2024 | 41 | $728.6M | SRRK, CRGX, SEPN, MLYS, NGNE |
| Q3 2024 | 40 | $520.3M | CRGX, MLYS, SRRK, NGNE, ALMS |
| Q2 2024 | 38 | $477.8M | CRGX, MLYS, SRRK, NGNE, ACLX |
| Q1 2024 | 37 | $646.3M | SRRK, CRGX, MLYS, NGNE, NKTX |